FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1570706955> ?p ?o ?g. }

• W1570706955 endingPage "e167" @default.
• W1570706955 startingPage "e167" @default.
• W1570706955 abstract "Abstract The forkhead transcription factor FOXK2 has recently been implicated in cancer cell proliferation and survival, but a role in cancer chemotherapeutic drug resistance has hitherto not been explored. Here we demonstrate that FOXK2 has a central role in mediating the cytotoxic drug response in breast cancer. Clonogenic and cell viability assays showed that enhanced FOXK2 expression sensitizes MCF-7 breast cancer cells to paclitaxel or epirubicin treatment, whereas FOXK2 depletion by small interfering RNAs (siRNAs) confers drug resistance. Our data also showed that the activation of the tumour suppressor FOXO3a by paclitaxel and epirubicin is mediated through the induction of FOXK2, as depletion of FOXK2 by siRNA limits the induction of FOXO3a by these drugs in MCF-7 cells. Chromatin immunoprecipitation (ChIP) analysis showed that in response to drug treatment, FOXK2 accumulates and binds to the proximal FOXO3a promoter region in MCF-7 cells. Furthermore, we also uncovered that FOXK2 is deregulated and, therefore, can express at high levels in the nucleus of both the paclitaxel and epirubicin drug-resistant MCF-7 cells. Our results showed that ectopically overexpressed FOXK2 accumulates in the nuclei of drug-resistant MCF-7 cells but failed to be recruited to target genes, including FOXO3a. Crucially, we found that FOXO3a is required for the anti-proliferative and epirubicin-induced cytotoxic function of FOXK2 in MCF-7 cells by sulphorhodamine and clonogenic assays. The physiological importance of the regulation of FOXO3a by FOXK2 is further confirmed by the significant correlations between FOXO3a and FOXK2 expression in breast carcinoma patient samples. Further survival analysis also reveals that high nuclear FOXK2 expression significantly associates with poorer clinical outcome, particularly in patients who have received conventional chemotherapy, consistent with our finding that FOXK2 is deregulated in drug-resistant cells. In summary, our results suggest that paclitaxel and epirubicin target the FOXK2 to modulate their cytotoxicity and deregulated FOXK2 confers drug resistance." @default.
• W1570706955 created "2016-06-24" @default.
• W1570706955 creator A5011563070 @default.
• W1570706955 creator A5014225681 @default.
• W1570706955 creator A5017040011 @default.
• W1570706955 creator A5020071379 @default.
• W1570706955 creator A5024442204 @default.
• W1570706955 creator A5027448873 @default.
• W1570706955 creator A5034475868 @default.
• W1570706955 creator A5041325189 @default.
• W1570706955 creator A5047298825 @default.
• W1570706955 creator A5079166449 @default.
• W1570706955 creator A5081840813 @default.
• W1570706955 creator A5083165919 @default.
• W1570706955 date "2015-09-07" @default.
• W1570706955 modified "2023-10-01" @default.
• W1570706955 title "Forkhead box K2 modulates epirubicin and paclitaxel sensitivity through FOXO3a in breast cancer" @default.
• W1570706955 cites W1603781996 @default.
• W1570706955 cites W1652264402 @default.
• W1570706955 cites W1895935492 @default.
• W1570706955 cites W1955107491 @default.
• W1570706955 cites W1963634341 @default.
• W1570706955 cites W1984101059 @default.
• W1570706955 cites W1985647633 @default.
• W1570706955 cites W1988975697 @default.
• W1570706955 cites W1991962407 @default.
• W1570706955 cites W1997863391 @default.
• W1570706955 cites W2012161830 @default.
• W1570706955 cites W2024290860 @default.
• W1570706955 cites W2028748220 @default.
• W1570706955 cites W2030805070 @default.
• W1570706955 cites W2047791731 @default.
• W1570706955 cites W2055807959 @default.
• W1570706955 cites W2067265742 @default.
• W1570706955 cites W2067831604 @default.
• W1570706955 cites W2076174368 @default.
• W1570706955 cites W2090546918 @default.
• W1570706955 cites W2096122358 @default.
• W1570706955 cites W2110354540 @default.
• W1570706955 cites W2113002082 @default.
• W1570706955 cites W2124006755 @default.
• W1570706955 cites W2138160712 @default.
• W1570706955 cites W2148899732 @default.
• W1570706955 cites W2149264287 @default.
• W1570706955 cites W2149883217 @default.
• W1570706955 cites W2157633567 @default.
• W1570706955 cites W2164836249 @default.
• W1570706955 cites W2165057403 @default.
• W1570706955 cites W2168734527 @default.
• W1570706955 doi "https://doi.org/10.1038/oncsis.2015.26" @default.
• W1570706955 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4767938" @default.
• W1570706955 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26344694" @default.
• W1570706955 hasPublicationYear "2015" @default.
• W1570706955 type Work @default.
• W1570706955 sameAs 1570706955 @default.
• W1570706955 citedByCount "24" @default.
• W1570706955 countsByYear W15707069552016 @default.
• W1570706955 countsByYear W15707069552017 @default.
• W1570706955 countsByYear W15707069552018 @default.
• W1570706955 countsByYear W15707069552019 @default.
• W1570706955 countsByYear W15707069552020 @default.
• W1570706955 countsByYear W15707069552021 @default.
• W1570706955 countsByYear W15707069552022 @default.
• W1570706955 crossrefType "journal-article" @default.
• W1570706955 hasAuthorship W1570706955A5011563070 @default.
• W1570706955 hasAuthorship W1570706955A5014225681 @default.
• W1570706955 hasAuthorship W1570706955A5017040011 @default.
• W1570706955 hasAuthorship W1570706955A5020071379 @default.
• W1570706955 hasAuthorship W1570706955A5024442204 @default.
• W1570706955 hasAuthorship W1570706955A5027448873 @default.
• W1570706955 hasAuthorship W1570706955A5034475868 @default.
• W1570706955 hasAuthorship W1570706955A5041325189 @default.
• W1570706955 hasAuthorship W1570706955A5047298825 @default.
• W1570706955 hasAuthorship W1570706955A5079166449 @default.
• W1570706955 hasAuthorship W1570706955A5081840813 @default.
• W1570706955 hasAuthorship W1570706955A5083165919 @default.
• W1570706955 hasBestOaLocation W15707069551 @default.
• W1570706955 hasConcept C109316439 @default.
• W1570706955 hasConcept C109541995 @default.
• W1570706955 hasConcept C117262875 @default.
• W1570706955 hasConcept C121608353 @default.
• W1570706955 hasConcept C126322002 @default.
• W1570706955 hasConcept C1491633281 @default.
• W1570706955 hasConcept C154317977 @default.
• W1570706955 hasConcept C185592680 @default.
• W1570706955 hasConcept C202751555 @default.
• W1570706955 hasConcept C22615655 @default.
• W1570706955 hasConcept C2776375370 @default.
• W1570706955 hasConcept C2777292972 @default.
• W1570706955 hasConcept C2780835546 @default.
• W1570706955 hasConcept C2994423619 @default.
• W1570706955 hasConcept C502942594 @default.
• W1570706955 hasConcept C530470458 @default.
• W1570706955 hasConcept C54009773 @default.
• W1570706955 hasConcept C54355233 @default.
• W1570706955 hasConcept C55493867 @default.
• W1570706955 hasConcept C71924100 @default.
• W1570706955 hasConcept C81885089 @default.

• next